Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622766 | 1.00 | ADORA1 (0.60) | ADORA1MAPTADORA2AL3MBTL1KMT2A | |
| SCHEMBL2960211 | 0.88 | ADORA1 (0.64) | ADORA1MAPTADORA2AL3MBTL1KMT2A | |
| SCHEMBL12785514 | 0.83 | ADORA1 (0.41) | ADORA1MAPTADORA2AL3MBTL1LMNA | |
| SCHEMBL13622765 | 0.81 | ADORA1 (0.57) | ADORA1MAPTADORA2AKMT2ALMNA | |
| SCHEMBL1536291 | 0.78 | ADORA1 (0.54) | ADORA1MAPTL3MBTL1KMT2ALMNA | |
| SCHEMBL24010808 | 0.77 | ADORA1 (0.38) | ADORA1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL29977503 | 0.77 | ADORA1 (0.38) | ADORA1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL9379563 | 0.76 | KDM4E (0.42) | ADORA1MAPTADORA2AKMT2ALMNA | |
| SCHEMBL13702956 | 0.76 | MAPT (0.37) | ADORA1MAPTKMT2ALMNAHTT | |
| SCHEMBL18529930 | 0.76 | KMT2A (0.53) | ADORA1MAPTADORA2AKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117597333-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 维吉尔神经科学股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| CN-115867284-A | Heterocyclic compounds as trigger receptor 2 agonists expressed on myeloid cells and methods of use | 安进公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4146222-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Amgen Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ADORA1 305/4885MAPT 681/4885ADORA2A 109/4885 |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ADORA1 305/4885MAPT 681/4885ADORA2A 109/4885 |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ADORA1 305/4885MAPT 681/4885ADORA2A 109/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ADORA1 305/4885MAPT 681/4885ADORA2A 109/4885 |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ADORA1 305/4885MAPT 681/4885ADORA2A 109/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ADORA1 305/4885MAPT 681/4885ADORA2A 109/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ADORA1 305/4885MAPT 681/4885ADORA2A 109/4885 |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ADORA1 305/4885MAPT 681/4885ADORA2A 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.